Journal
NATURE REVIEWS NEUROLOGY
Volume 9, Issue 1, Pages 13-24Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2012.242
Keywords
-
Categories
Funding
- UK Medical Research Council [U105184291]
- Parkinson's UK
- Deutsche Forschungsgemeinschaft [TR 1000/1-1]
- MRC [MC_U105184291] Funding Source: UKRI
- Medical Research Council [MC_U105184291] Funding Source: researchfish
- Parkinson"
- s UK [G-1102, K-1012] Funding Source: researchfish
Ask authors/readers for more resources
In 1817, James Parkinson described the symptoms of the shaking palsy, a disease that was subsequently defined in greater detail, and named after Parkinson, by Jean-Martin Charcot. Parkinson expected that the publication of his monograph would lead to a rapid elucidation of the anatomical substrate of the shaking palsy; in the event, this process took almost a century. In 1912, Fritz Heinrich Lewy identified the protein aggregates that define Parkinson disease (PD) in some brain regions outside the substantia nigra. In 1919, Konstantin Nikolaevich Tretiakoff found similar aggregates in the substantia nigra and named them after Lewy. In the 1990s, alpha-synuclein was identified as the main constituent of the Lewy pathology, and its aggregation was shown to be central to PD, dementia with Lewy bodies, and multiple system atrophy. In 2003, a staging scheme for idiopathic PD was introduced, according to which alpha-synuclein pathology originates in the dorsal motor nucleus of the vagal nerve and progresses from there to other brain regions, including the substantia nigra. In this article, we review the relevance of Lewy's discovery 100 years ago for the current understanding of PD and related disorders. Goedert, M. et al. Nat. Rev. Neurol. 9, 13-24 (2013); published online 27 November 2012; doi:10.1038/nrneurol.2012.242
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available